Diabetogenic Effect of a Series of Tricyclic Delta Opioid Agonists Structurally Related to Cyproheptadine
Authors:
Open Access
- 8 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 117 (2) , 493-504
Abstract
The unexpected observation of a hyperglycemic effect of some tricycle-based delta opioid receptor (DOR) agonists led to a series of studies to better understand the finding. Single administration of two novel tricyclic DOR agonists dose dependently elevated rat plasma glucose levels; 4-week toxicology studies confirmed the hyperglycemic finding and further revealed pancreatic β-cell hypertrophy, including vacuole formation, as well as bone dysplasia and Harderian gland degeneration with regeneration. Similar diabetogenic effects were observed in dog. A review of the literature on the antiserotonergic and antihistaminergic drug cyproheptadine (CPH) and its metabolites revealed shared structural features as well as similar hyperglycemic effects to the present series of DOR agonists. To further evaluate these effects, we established an assay measuring insulin levels in the rat pancreatic β-cell–derived RINm5F cell line, extensively used to study CPH and its metabolites. Like CPH, the initial DOR agonists studied reduced RINm5F cell insulin levels in a concentration-dependent manner. Importantly, compound DOR potency did not correlate with the insulin-reducing potency. Furthermore, the RINm5F cell insulin results correlated with the diabetogenic effect of the compounds in a 5-day mouse study. The RINm5F cell insulin assay enabled the identification of aryl-aryl-amine DOR agonists that lacked an insulin-reducing effect and did not elevate blood glucose in repeated dosing studies conducted over a suprapharmacologic dose range. Thus, not only did the RINm5F cell assay open a path for the further discovery of DOR agonists lacking diabetogenic potential but also it established a reliable, economical, and high-throughput screen for such potential, regardless of chemotype or target pharmacology. The present findings also suggest a mechanistic link between the toxicity observed here and that underlying Wolcott-Rallison Syndrome.Keywords
This publication has 24 references indexed in Scilit:
- JNJ-20788560 [9-(8-Azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic Acid Diethylamide], a Selective Delta Opioid Receptor Agonist, Is a Potent and Efficacious Antihyperalgesic Agent That Does Not Produce Respiratory Depression, Pharmacologic Tolerance, or Physical DependenceThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216The Journal of Pharmacology and Experimental Therapeutics, 2006
- Inhibition of Insulin Synthesis by Cyproheptadine: Effects on TranslationToxicological Sciences, 2004
- Wolcott-Rallison syndrome: pathogenic insights into neonatal diabetes from new mutation and expression studies of EIF2AK3Journal of Medical Genetics, 2003
- EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndromeNature Genetics, 2000
- Pharmacokinetics of Cyproheptadine and Its Metabolites in Rats.Biological and Pharmaceutical Bulletin, 1993
- Cyproheptadine metabolites inhibit proinsulin and insulin biosynthesis and insulin release in isolated rat pancreatic isletsCell Biology and Toxicology, 1989
- Cyproheptadine Inhibits (Pro)Insulin Biosynthesis and Secretion of Isolated Human Pancreatic IsletsHormone and Metabolic Research, 1981
- Isomeric specificity of diphenylmethylpiperidine in the production of rat pancreatic islet cell toxicityToxicology, 1977
- Structure-Activity Relationships in the Cyproheptadine SeriesJournal of Medicinal Chemistry, 1965